Literature DB >> 21963733

Diagnostic value of serum procalcitonin and C-reactive protein for infections after allogeneic hematopoietic stem cell transplantation versus nontransplant setting.

Yasuo Mori1, Kohta Miyawaki, Koji Kato, Katsuto Takenaka, Hiromi Iwasaki, Naoki Harada, Toshihiro Miyamoto, Koichi Akashi, Takanori Teshima.   

Abstract

OBJECTIVE: Procalcitonin (PCT) has been increasingly used as a biomarker of infection. The purpose of this study was to evaluate its diagnostic value after hematopoietic stem cell transplantation (HSCT), where non-infectious febrile complications such as graft-versus-host disease frequently develop.
METHODS: We retrospectively analyzed 144 febrile episodes (infections: 82, and noninfections: 62) in adult patients with hematological disorders, including 57 and 87 episodes in HSCT and non-HSCT patients, respectively.
RESULTS: Of 57 febrile episodes in HSCT patients, 46 (86%) and 25 (44%) revealed positivity for C-reactive protein (CRP) and PCT, respectively. Among 87 febrile episodes in non-HSCT patients, 81 (93%) and 22 (25%) events showed positive results of CRP and PCT. Both of these biomarkers were associated with infectious episodes in univariate analysis. Multivariate analysis showed that a high cut-off level (>9.5 mg/dL) of CRP was a better indicator for infections than PCT in HSCT patients, while PCT positivity was more diagnostic for infections than any cutoff CRP level in non-HSCT patients.
CONCLUSION: It may be necessary to interpret the results of these biomarkers with different orders of priority in transplant versus nontransplant patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21963733     DOI: 10.2169/internalmedicine.50.5798

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  7 in total

1.  Risk factor for death in hematopoietic stem cell transplantation: are biomarkers useful to foresee the prognosis in this population of patients?

Authors:  K S R Massaro; R Macedo; B S de Castro; F Dulley; M S Oliveira; M A S Yasuda; A S Levin; S F Costa
Journal:  Infection       Date:  2014-09-30       Impact factor: 3.553

2.  Prediction of infectious complications by the combination of plasma procalcitonin level and localized infection before allogeneic hematopoietic cell transplantation.

Authors:  M Sato; H Nakasone; K Terasako-Saito; K Sakamoto; R Yamazaki; Y Tanaka; Y Akahoshi; H Nakano; T Ugai; H Wada; R Yamasaki; Y Ishihara; K Kawamura; M Ashizawa; S-i Kimura; M Kikuchi; A Tanihara; J Kanda; S Kako; J Nishida; Y Kanda
Journal:  Bone Marrow Transplant       Date:  2014-01-13       Impact factor: 5.483

Review 3.  Possible implication of bacterial infection in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Authors:  Shigeo Fuji; Markus Kapp; Hermann Einsele
Journal:  Front Oncol       Date:  2014-04-24       Impact factor: 6.244

4.  Neck infection after allogenic hematopoietic progenitors transplantation.

Authors:  J Mensa; C Dueñas Gutiérrez; C Cardozo; L Rodríguez Fernández; M Kestler; P Muñoz; E Bouza
Journal:  Rev Esp Quimioter       Date:  2020-02-14       Impact factor: 1.553

5.  The clinical value of biomarkers in respiratory complications in hematopoietic SCT.

Authors:  C M Lucena; M Rovira; A Gabarrús; X Filella; C Martínez; R Domingo; A Torres; C Agustí
Journal:  Bone Marrow Transplant       Date:  2016-10-31       Impact factor: 5.483

Review 6.  Rapid clinical bacteriology and its future impact.

Authors:  Alex van Belkum; Géraldine Durand; Michel Peyret; Sonia Chatellier; Gilles Zambardi; Jacques Schrenzel; Dee Shortridge; Anette Engelhardt; William Michael Dunne
Journal:  Ann Lab Med       Date:  2012-12-17       Impact factor: 3.464

7.  Serum procalcitonin as an independent diagnostic markers of bacteremia in febrile patients with hematologic malignancies.

Authors:  Mina Yang; Seung Jun Choi; Jaewoong Lee; Dong Gun Lee; Yoon-Joo Kim; Yeon-Joon Park; Eun-Jee Oh
Journal:  PLoS One       Date:  2019-12-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.